Thrive Wealth Management LLC Sells 4,487 Shares of GSK plc (NYSE:GSK)

Thrive Wealth Management LLC cut its stake in GSK plc (NYSE:GSK) by 38.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,249 shares of the pharmaceutical company’s stock after selling 4,487 shares during the quarter. Thrive Wealth Management LLC’s holdings in GSK were worth $245,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. FMR LLC lifted its holdings in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in GSK during the second quarter valued at $52,487,000. Fisher Asset Management LLC raised its stake in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its stake in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in GSK by 33.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock valued at $86,875,000 after purchasing an additional 569,614 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Trading Up 0.0 %

NYSE GSK opened at $33.46 on Monday. The company’s 50-day moving average price is $34.02 and its 200-day moving average price is $37.98. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a market cap of $69.34 billion, a PE ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.70%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is presently 96.10%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GSK. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.